On October 30, Gelonhui announced that Pharmaron Biotech (688046.SH) released a statement, achieving revenue of 0.51 billion yuan in the first three quarters of 2024, an increase of 12.13% year-on-year; the net income attributable to shareholders of the listed company was 98.2144 million yuan, a decrease of 16.57% year-on-year, with basic earnings per share of 0.24 yuan.
药康生物(688046.SH)：前三季度实现净利润9821.44万元
Yao Kang Biology (688046.SH): Achieved net income of 98.2144 million yuan in the first three quarters.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th